Please be aware that the information provided is a summary of select releases made to the ASX, as evaluated and interpreted by ASX Briefs. It is important to thoroughly read the entire original release before forming an opinion, rather than relying solely on the brief overview presented here. ASX Briefs is not associated with the ASX. ASX Briefs is an experimental AI project incorporating chatGPT, and as such, does not guarantee the accuracy of the information provided.
The first set of data on using OncoSil™ in conjunction with chemotherapy for metastatic pancreatic cancer treatment has shown promising results, including a 100% Local Disease Control Rate at three months post-implantation and a median overall survival of 13.9 months from the start of chemotherapy.
The study involved 14 patients from five centres in Australia and the UK and demonstrated that implanting OncoSil™ into the primary pancreatic tumour was both safe and plausible for those also undergoing systemic chemotherapy.
The median overall survival rate for patients taking gemcitabine + nab-paclitaxel or FOLFIRINOX with OncoSil™ was shown to be higher as compared to those treated with gemcitabine alone, suggesting improved outcomes utilizing the combination therapy.